Doloromics Overview
- Year Founded
-
2020
- Status
-
Out of Business
- Employees
-
10
- Latest Deal Type
-
Out of Business
- Investors
-
1
Doloromics General Information
Description
Developer of pharmaceutical and therapeutic drugs designed to produce drugs for neuropathic therapy and inflammation reduction. The company aims to uncover disease-specific pain mechanisms to develop biomarkers and therapeutics to treat inflammatory and chronic pain and help to capitalize on the human data-guided target identification and validation platform, enabling patients to get quick chronic pain relief from numerous types of severe pain and neuropathies.
Contact Information
Website
www.doloromics.comCorporate Office
- 3515 Edison Way
- Suite C
- Menlo Park, CA 94025
- United States
Corporate Office
- 3515 Edison Way
- Suite C
- Menlo Park, CA 94025
- United States
Doloromics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 05-Mar-2025 | Completed | Out of Business | |||
| 4. Early Stage VC | 01-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 22-Feb-2022 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 08-Feb-2021 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | 01-Jan-2020 | Completed | Startup |
Doloromics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 92,357 | $0.001000 | $1.54 | $1.54 | 1x | $1.54 | 1.48% | |
| Seed-1 | 156,769 | $0.001000 | $1.35 | $1.35 | 1x | $1.35 | 2.52% |
Doloromics Comparisons
Industry
Financing
Details
Doloromics Competitors (2)
One of Doloromics’s 2 competitors is Eptiva Theraputics, a Accelerator/Incubator Backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eptiva Theraputics | Accelerator/Incubator Backed | Oxford, United Kingdom | ||||
| AnaBios | Venture Capital-Backed | San Diego, CA |
Doloromics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Doloromics Patents
Doloromics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240302351-A1 | Platform for target discovery and methods of use thereof | Pending | 28-Feb-2023 |
Doloromics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Doloromics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of Texas at Dallas | University |
Doloromics FAQs
-
When was Doloromics founded?
Doloromics was founded in 2020.
-
Where is Doloromics headquartered?
Doloromics is headquartered in Menlo Park, CA.
-
What is the size of Doloromics?
Doloromics has 10 total employees.
-
What industry is Doloromics in?
Doloromics’s primary industry is Drug Discovery.
-
Is Doloromics a private or public company?
Doloromics is a Private company.
-
What is Doloromics’s current revenue?
The current revenue for Doloromics is .
-
How much funding has Doloromics raised over time?
Doloromics has raised $4.6M.
-
Who are Doloromics’s investors?
University of Texas at Dallas has invested in Doloromics.
-
Who are Doloromics’s competitors?
Eptiva Theraputics and AnaBios are competitors of Doloromics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
